Results 211 to 220 of about 44,829 (223)

Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.

ACS Medicinal Chemistry Letters, 2018
Kun Fang, Guoqiang Dong, Y. Li, Shipeng He, Ying Wu, Shanchao Wu, Wen Wang, C. Sheng   +7 more
semanticscholar   +1 more source

Improved automated one-pot two-step radiosynthesis of (S)-[¹⁸F]FETrp, a radiotracer for PET imaging of indoleamine 2,3-dioxygenase 1 (IDO1). [PDF]

EJNMMI Radiopharm Chem
Maisonial-Besset A, Kryza D, Kopka K, Levesque S, Moreau E, Wenzel B, Chezal JM.   +6 more
europepmc   +1 more source

In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis [PDF]

, 2017
Khader, Shabaana A.
core   +1 more source

The Pig as a Large Animal Model for Studying Anti-Tumor Immune Responses [PDF]

, 2017
Overgaard, Nana Haahr
core  

Tryptophan metabolism and its relationship with immune activation, depression, and neurocognitive impairment among HIV-infected individuals [PDF]

, 2013
Boasso, A, Chittiprol, S, Ellis, RJ, Fuchs, D, Keegan, MR, Letendre, S, Winston, A   +6 more
core   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Discovery of Clinical Candidate (1 R,4 r)-4-(( R)-2-(( S)-6-Fluoro-5 H-imidazo[5,1- a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1.

Journal of Medicinal Chemistry, 2019
A novel class of 5-substituted 5 H-imidazo[5,1- a]isoindoles are described as potent inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1). A structure-based drug design approach was used to elaborate the 5 H-imidazo[5,1- a]isoindole core and to improve ...
Sanjeev Kumar, J. Waldo, Firoz A. Jaipuri, Agnieszka Marcinowicz, Clarissa Van Allen, James Adams, Tanay Kesharwani, Xiaoxia Zhang, R. Metz, A. Oh, S. Harris, M. Mautino   +11 more
semanticscholar   +1 more source

Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.

Journal of Medicinal Chemistry, 2020
Indoleamine 2,3-dioxygenase 1 (IDO1) has received increasing attention due to its immunosuppressive function in connection with various diseases, including cancer.
Xi Feng, Dongdong Liao, Dongyu Liu, An Ping, Zhiyu Li, Jinlei Bian   +5 more
semanticscholar   +1 more source

Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1.

Journal of Medicinal Chemistry, 2016
Yi-Hui Peng, S. Ueng, C. Tseng, M. Hung, Jen‐Shin Song, Jian‐Sung Wu, Fang-Yu Liao, Yu-Shiou Fan, Mine-Hsine Wu, Wen‐chi Hsiao, Ching-Cheng Hsueh, Shu-Yu Lin, Chia-Yi Cheng, Chih-Hsiang Tu, Lung-Chun Lee, Ming-Fu Cheng, Kak‐Shan Shia, C. Shih, Su-Ying Wu   +18 more
semanticscholar   +1 more source

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma

Investigational new drugs, 2020
D. Reardon, A. Desjardins, O. Rixe, T. Cloughesy, S. Alekar, Jason H. Williams, Ray Li, C. Taylor, A. Lassman   +8 more
semanticscholar   +1 more source